Physician profile
John Losee
NPI 1932138906
$8,763.82
in general payments reported to CMS, 2019-2025
42 companies · $5,080 in 2025
The $5,080 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $379 · 2021: $808 · 2022: $1,067 · 2023: $422 · 2024: $596 · 2025: $5,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,022 · Travel and Lodging: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,021.67 |
| Travel and Lodging | $2,076.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,871.80 | 2023-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $1,216.20 | 2020-2025 | Solyx Sis System, Ams 700, General - Therapies |
| Astellas Pharma US INC | $1,009.24 | 2019-2025 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $995.04 | 2025 | |
| Axonics, INC. | $474.52 | 2022-2024 | Axonics |
| Sumitomo Pharma America, INC. | $332.69 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $263.61 | 2019-2025 | |
| Urogen Pharma, INC. | $241.71 | 2020-2025 | |
| Urovant Sciences INC | $229.23 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $212.39 | 2019-2022 | |
| Antares Pharma, INC. | $159.18 | 2019-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $144.23 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Janssen Pharmaceuticals, INC | $124.21 | 2019-2021 | |
| Renovia INC | $124.10 | 2019 | |
| Abbvie INC. | $112.22 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $110.77 | 2024-2025 | Xiaflex |
| Medtronic, INC. | $104.60 | 2021-2025 | Interstim |
| Corcept Therapeutics | $95.87 | 2021 | |
| Myriad Genetic Laboratories, INC. | $94.91 | 2024-2025 | Prolaris |
| Myovant Sciences INC. | $92.87 | 2021-2022 | |
| Profound Medical Corp. | $70.54 | 2025 | Tulsa-Pro |
| Bayer Healthcare Pharmaceuticals INC. | $67.78 | 2021-2025 | |
| Janssen Biotech, INC. | $61.94 | 2022-2025 | Erleada, Balversa, Akeega |
| Amarin Pharma, INC. | $53.32 | 2020-2021 | |
| Tolmar, INC. | $52.79 | 2025 | Jatenzo |
| Allergan, INC. | $43.70 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $41.08 | 2022 | |
| Laborie Medical Technologies Corp. | $38.97 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Olympus America INC. | $36.41 | 2024-2025 | Soltive, Olympus |
| Coloplast Corp | $34.38 | 2021-2024 | |
| Calyxo, INC. | $33.69 | 2025 | Cvac Aspiration System |
| Arbor Pharmaceuticals, INC. | $32.56 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $32.06 | 2024-2025 | Adstiladrin |
| Becton, Dickinson and Company | $30.05 | 2025 | Bard Urinary Drainage Bag |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.45 | 2020 | |
| 180 Medical, INC. | $19.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.01 | 2025 | |
| Amgen INC. | $16.72 | 2019 | |
| Verity Pharmaceuticals INC. | $15.24 | 2025 | Tlando |
| Ambu INC. | $13.66 | 2022 | |
| Therapeuticsmd, INC. | $11.51 | 2019 | |
| Metuchen Pharmaceuticals | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Losee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.